CN114209878A - Solid phase powder for bone cement composite material, bone cement composite material and application - Google Patents

Solid phase powder for bone cement composite material, bone cement composite material and application Download PDF

Info

Publication number
CN114209878A
CN114209878A CN202111439934.1A CN202111439934A CN114209878A CN 114209878 A CN114209878 A CN 114209878A CN 202111439934 A CN202111439934 A CN 202111439934A CN 114209878 A CN114209878 A CN 114209878A
Authority
CN
China
Prior art keywords
phosphate
bone cement
powder
cement composite
composite material
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202111439934.1A
Other languages
Chinese (zh)
Other versions
CN114209878B (en
Inventor
李梅
张海燕
李祥瑞
董骧
许书富
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Natong Medical Research Institute Co ltd
Tianjin Zhengtian Medical Instrument Co Ltd
Original Assignee
Beijing Natong Medical Research Institute Co ltd
Tianjin Zhengtian Medical Instrument Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Natong Medical Research Institute Co ltd, Tianjin Zhengtian Medical Instrument Co Ltd filed Critical Beijing Natong Medical Research Institute Co ltd
Priority to CN202111439934.1A priority Critical patent/CN114209878B/en
Publication of CN114209878A publication Critical patent/CN114209878A/en
Application granted granted Critical
Publication of CN114209878B publication Critical patent/CN114209878B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02—Inorganic materials
    • A61L27/10—Ceramics or glasses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02—Inorganic materials
    • A61L27/12—Phosphorus-containing materials, e.g. apatite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/42—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix
    • A61L27/425—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix of phosphorus containing material, e.g. apatite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Composite Materials (AREA)
  • Materials Engineering (AREA)
  • Ceramic Engineering (AREA)
  • Materials For Medical Uses (AREA)

Abstract

The invention discloses a bone cement composite material, which comprises solid phase powder and solidification liquid, wherein the solid phase powder comprises calcium phosphate powder, calcium sulfate hemihydrate powder, bioglass and hydroxyapatite, and the calcium phosphate powder comprises: beta-tricalcium phosphate, tetracalcium phosphate and monocalcium phosphate monohydrate. Wherein the solid phase powder comprises 10-80% of calcium phosphate powder, 5-50% of bioglass, 10-25% of calcium sulfate hemihydrate powder and 5-15% of hydroxyapatite by mass percentage. The bone cement prepared from the composite material has high strength, good antibacterial property and injectability, keeps good biological activity, is not easy to collapse in the using process, and can be applied to filling and repairing of bone defect parts in the fields of orthopedics, plastic surgery, dentistry and the like.

Description

Solid phase powder for bone cement composite material, bone cement composite material and application
Technical Field
The invention belongs to the field of bone repair materials, and particularly relates to solid-phase powder for a bone cement composite material, and particularly relates to the bone cement composite material and application thereof.
Background
Bone cement is a common orthopedic repair material and is widely applied to the fields of bone defects, dentistry, plastic surgery and the like. Currently, most of the common bone cement materials on the market are polymethylmethacrylate bone cement (PMMA). The material system is non-absorbable, has low bioactivity and no good bone induction capability, and releases a large amount of heat in the curing process to cause damage to surrounding tissues. Therefore, a more suitable orthopedic repair material is required.
The calcium phosphate cement consists of solid calcium phosphate powder and liquid phase, and the mixture of the solid calcium phosphate powder and the liquid phase can be solidified in physiological environment. The curing process has no great heat generation, and the product is hydroxyapatite similar to inorganic components in human skeleton. In addition, the material system has good biological activity, osteoinductivity and absorbability, and can stimulate the rapid generation of new bone tissues when being implanted into a body. Although calcium phosphate cement is more suitable for bone repair than polymethylmethacrylate bone cement in a material system, the traditional calcium phosphate bone cement still has some problems and cannot meet clinical requirements. Firstly, the strength is low, the mechanical property of the calcium phosphate cement is close to that of cancellous bone, and the calcium phosphate cement can only be used for bone defect of a non-bearing part and cannot meet the requirement of clinical load-bearing bone repair. Secondly, the curing time is not matched with clinical requirements, the ideal bone cement curing time in the operation is 15-30 min, and the curing time of different calcium phosphate systems is too fast or too slow to adapt to the clinical requirements on the curing time. And thirdly, the injection performance is poor, the solid-liquid separation phenomenon is easy to occur in the injection process, the injection rate is low, the material waste is caused, and the clinical requirement of the minimally invasive surgery cannot be met. Then, the medicine is easy to be dispersed, and the medicine is washed by body fluid or blood and cannot be shaped in the operation process. Finally, the calcium phosphate bone cement has no antibacterial property, inflammation caused by bacterial infection is a key factor causing operation failure in an orthopedic implantation operation, the traditional calcium phosphate bone cement has no good antibacterial property, and if the bone cement has good antibacterial property, inflammatory reaction caused by bacterial infection can be effectively reduced, bone healing is promoted, and the success rate of the operation is improved. Therefore, there is a need to develop a new bone cement material to meet the current clinical needs.
Disclosure of Invention
The present invention is based on the discovery and recognition by the inventors of the following facts and problems: the traditional calcium phosphate bone cement has low strength, poor injectability, easy collapsibility, unmatched curing time with ideal requirements of operations, no antibacterial property and incapability of meeting clinical requirements.
The present invention is directed to solving, at least to some extent, one of the technical problems in the related art.
Therefore, the solid phase powder for the bone cement composite material provided by the embodiment of the invention improves the components of the calcium phosphate material to perform multiphase curing reaction, so that the strength is improved, and the solid phase powder applied to the calcium phosphate bone cement not only has high strength, good antibacterial property and injectability, but also maintains good biological activity and is not easy to collapse in the using process, so that the solid phase powder can be applied to filling and repairing of bone defect parts in the fields of orthopedics, plastic surgery, dentistry and the like.
The solid phase powder for the bone cement composite material comprises calcium phosphate powder, calcium sulfate hemihydrate powder, bioglass and hydroxyapatite, wherein the calcium phosphate powder comprises: beta-tricalcium phosphate, tetracalcium phosphate and monocalcium phosphate monohydrate.
The solid phase powder for the bone cement composite material of the embodiment of the invention brings advantages and technical effects, 1, in the embodiment of the invention, through the design of the components of the solid phase powder, the multi-phase solidification reaction is generated in the reaction phase, so that the strength can be improved in multiple ways, beta-tricalcium phosphate and mono-hydrated calcium dihydrogen phosphate in a calcium phosphate material system can be quickly reacted in a liquid phase environment to generate calcium hydrogen phosphate dihydrate, and the generated calcium hydrogen phosphate dihydrate and tetracalcium phosphate are slowly chemically reacted in the liquid phase environment to generate hydroxyapatite, wherein the reaction rate of the beta-tricalcium phosphate and the mono-hydrated calcium dihydrogen phosphate in the calcium phosphate material system is high, the solidification time is short, the reaction can be completed in about 1min, the reaction rate of the calcium hydrogen phosphate dihydrate and the tetracalcium phosphate is low, the solidification time is long, and the solidification is about 50-120 min, the multi-gradient chemical reaction is designed primarily, the calcium phosphate cement binding phase can be promoted to be more compact, so that the strength of the calcium phosphate cement binding phase is effectively improved; 2. in the embodiment of the invention, the hydroxyapatite added into the solid phase powder can provide nucleation sites for the hydroxyapatite generated by the reaction in the system, accelerate the reaction of calcium hydrogen phosphate dihydrate and tetracalcium phosphate to generate hydroxyapatite and shorten the curing time; 3. in the embodiment of the invention, when the solid-phase powder is applied to the bone cement composite material, the calcium sulfate hemihydrate reacts with the liquid phase to generate the calcium sulfate dihydrate, the calcium sulfate has higher degradation rate in body fluid, and the degradation performance of the bone cement can be directionally prepared by doping the calcium sulfate hemihydrate in a calcium phosphate system so as to be matched with the growth of human bones; 4. in the embodiment of the invention, the bioglass in the solid phase powder has higher activity, can better stimulate and induce osteoblast gene expression and promote cell ossification, and meanwhile, the bioglass has good antibacterial performance and can improve the antibacterial performance of the bone cement when being doped into calcium phosphate bone cement.
In some embodiments, the solid phase powder comprises 10-80% of calcium phosphate powder, 5-50% of bioglass, 10-25% of calcium sulfate hemihydrate powder and 5-15% of hydroxyapatite by mass percentage.
In some embodiments, the calcium phosphate powder comprises 5-20% of beta-tricalcium phosphate, 60-90% of tetracalcium phosphate and 5-20% of monocalcium phosphate monohydrate by mass percentage.
The embodiment of the invention also provides application of the solid-phase powder for the bone cement composite material in preparing a bone repair material. The solid phase powder provided by the embodiment of the invention can be used for preparing a bone repair material, and the bone repair material has the corresponding advantages brought by the solid phase powder provided by the embodiment of the invention, and is not described again.
The embodiment of the invention also provides a bone cement composite material which comprises the solid-phase powder and the curing liquid. The composite material disclosed by the embodiment of the invention has excellent biocompatibility, the curing time can meet the ideal requirement of a surgical operation, and meanwhile, the antibacterial property and the injectability are maintained, so that the composite material can be applied to filling and repairing of bone defect parts in the fields of orthopedics, plastic surgery, dentistry and the like.
In some embodiments, the liquid-solid ratio of the solidification liquid to the solid-phase powder is 0.5ml/g to 1 ml/g.
In some embodiments, the curing liquid comprises dipotassium hydrogen phosphate, potassium dihydrogen phosphate, citric acid, and water.
In some embodiments, the solidifying fluid further comprises a polymeric compound comprising at least one of sodium alginate or hyaluronic acid.
In some embodiments, the curing liquid comprises 5-20% of dipotassium hydrogen phosphate, 5-20% of monopotassium hydrogen phosphate, 5-10% of citric acid, 1-5% of high molecular compound and the balance of water by mass percentage.
The invention also provides application of the bone cement composite material in preparing a bone repair material. The composite material provided by the embodiment of the invention can be used for preparing a bone repair material, has the corresponding advantages brought by the composite material provided by the embodiment of the invention, and is not described again.
Drawings
FIG. 1 is an XRD pattern of a solidified liquid and a solid powder at different times after mixing in example 1;
FIG. 2 is a graph showing a test of setting time of a bone cement composite according to an embodiment of the present invention;
FIG. 3 is a graph of the compressive strength of a bone cement composite hydrated for 24 hours according to an embodiment of the present invention;
FIG. 4 is a graph of the activity of cellular ALP after 7 days of co-culture of a bone cement composite with BMSCs cells according to an embodiment of the present invention;
FIG. 5 is a graph of time versus mass loss for a bone cement composite soaked in an SBF solution according to an embodiment of the present invention;
FIG. 6 is the OD value measured at 475nm wavelength after 48h of co-culture of the bone cement composite material of the example of the present invention with Staphylococcus aureus.
Detailed Description
Reference will now be made in detail to embodiments of the present invention, examples of which are illustrated in the accompanying drawings. The embodiments described below with reference to the drawings are illustrative and intended to be illustrative of the invention and are not to be construed as limiting the invention.
The solid phase powder for the bone cement composite material comprises calcium phosphate powder, calcium sulfate hemihydrate powder, bioglass and hydroxyapatite, wherein the calcium phosphate powder comprises: beta-tricalcium phosphate, tetracalcium phosphate and monocalcium phosphate monohydrate.
The solid phase powder for the bone cement composite material of the embodiment of the invention enables a multi-phase curing reaction to occur in the reaction phase through the design of the components of the solid phase powder, so that the strength can be improved in multiple ways, the beta-tricalcium phosphate and the monocalcium phosphate monohydrate in the calcium phosphate material system can quickly react in a liquid phase environment to generate calcium hydrophosphate dihydrate, the generated calcium hydrophosphate dihydrate and the generated tetracalcium phosphate slowly react in the liquid phase environment to generate hydroxyapatite, wherein, the reaction rate of the beta-tricalcium phosphate and the monohydrate monocalcium phosphate in the calcium phosphate system is high, the curing time is short, the reaction rate of the calcium hydrogen phosphate dihydrate and the tetracalcium phosphate is low, the curing time is long, and the multi-gradient chemical reaction is designed in the invention, so that the calcium phosphate cement binding phase can be more compact, and the strength of the calcium phosphate cement binding phase is effectively improved; in the embodiment of the invention, the hydroxyapatite added into the solid phase powder can provide nucleation sites for the hydroxyapatite generated by the reaction in the system, accelerate the reaction of calcium hydrogen phosphate dihydrate and tetracalcium phosphate to generate hydroxyapatite and shorten the curing time; in the embodiment of the invention, when the solid-phase powder is applied to the bone cement composite material, the calcium sulfate hemihydrate reacts with the liquid phase to generate the calcium sulfate dihydrate, the calcium sulfate has higher degradation rate in body fluid, and the degradation performance of the bone cement can be directionally prepared by doping the calcium sulfate hemihydrate in a calcium phosphate system so as to be matched with the growth of human bones; in the embodiment of the invention, the bioglass in the solid phase powder has higher activity, can better stimulate and induce osteoblast gene expression and promote cell ossification, and meanwhile, the bioglass has good antibacterial performance and can improve the antibacterial performance of the bone cement when being doped into calcium phosphate bone cement.
The reaction equation involved in the examples of the present invention is as follows:
in the calcium phosphate material system, beta-tricalcium phosphate and calcium dihydrogen phosphate monohydrate can react quickly in a liquid phase environment to generate calcium hydrogen phosphate dihydrate.
β-Ca3(PO4)2+Ca(H2PO4)2·H2O+7H2O→4CaHPO4·2H2O (1)
Subsequently, as shown in reaction equations (2) and (3), the generated calcium hydrogen phosphate dihydrate and tetracalcium phosphate slowly undergo a chemical reaction in a liquid phase environment to generate hydroxyapatite.
2Ca4(PO4)2O+2CaHPO4·2H2O→Ca10(PO4)6(OH)2+4H2O+2XCa(OH)2 (2)
2Ca4(PO4)2O+2CaHPO4·2H2O→Ca10-X(HPO4)X(PO4)6-X(OH)2-X+XCa(OH)2+(4-X)H2O(3)
The calcium phosphate system provided by the embodiment of the invention has the advantages that the reaction rate of tricalcium phosphate and monocalcium phosphate monohydrate is high, the reaction can be completed within 1min, the reaction rate of calcium hydrophosphate dihydrate and tetracalcium phosphate is low, the curing time is long, and the calcium hydrophosphate and the tetracalcium phosphate are primarily cured within 50-120 min.
Meanwhile, when the calcium sulfate hemihydrate powder is applied to a bone cement composite material, calcium sulfate dihydrate is generated by the reaction of the calcium sulfate hemihydrate powder and a liquid phase, as shown in formula (4), so that the degradation performance of the bone cement composite material can be effectively adjusted.
CaSO4·0.5H2O+1.5H2O→CaSO4·2H2O (4)
In some embodiments, the solid phase powder comprises 10-80% of calcium phosphate powder, 5-50% of bioglass, 10-25% of calcium sulfate hemihydrate powder and 5-15% of hydroxyapatite by mass percentage. More preferably, the calcium phosphate powder comprises 5-20% of beta-tricalcium phosphate, 60-90% of tetracalcium phosphate and 5-20% of monocalcium phosphate monohydrate by mass percentage. Too much hydroxyapatite can affect the mechanical property of the bone cement, and too little hydroxyapatite can reduce the provided nucleation sites, which is not beneficial to effectively promoting the solidification reaction. The pure calcium sulfate hemihydrate system has the advantages of fast degradation, short setting time and lower mechanical property than a calcium phosphate system, and the excessive addition of the calcium sulfate hemihydrate can shorten the setting time, accelerate the degradation speed and reduce the mechanical property of the bone cement. The bioglass has good biological activity and antibacterial property, but the mechanical property of the bone cement is reduced due to excessive addition. In the embodiment of the invention, the dosage of each substance in the solid phase powder is optimized, and the comprehensive performance of the bone cement is effectively improved.
The preparation method of the solid phase powder for the bone cement composite material comprises the following steps:
a. preparing calcium phosphate powder: mixing and grinding beta-tricalcium phosphate, tetracalcium phosphate and monocalcium phosphate monohydrate in a designed proportion, and uniformly mixing to obtain calcium phosphate powder;
b. preparing solid-phase powder: and c, mixing and grinding the calcium phosphate powder which is prepared in the step a and can be subjected to multi-step curing reaction, calcium sulfate hemihydrate powder, bioglass and hydroxyapatite according to a designed proportion, and uniformly mixing to obtain solid-phase powder.
The preparation method of the solid phase powder provided by the embodiment of the invention is simple and easy to operate, only needs grinding and mixing, and is easy for industrial application.
The embodiment of the invention also provides a bone cement composite material which comprises the solid-phase powder and the curing liquid. The composite material disclosed by the embodiment of the invention has excellent biocompatibility, the curing time can meet the ideal requirement of a surgical operation, and meanwhile, the antibacterial property and the injectability are maintained, so that the composite material can be applied to filling and repairing of bone defect parts in the fields of orthopedics, plastic surgery, dentistry and the like.
In some embodiments, the liquid-solid ratio of the solidification liquid to the solid-phase powder is 0.5ml/g to 1 ml/g. If the liquid-solid ratio is too high, the setting time is prolonged, and if the water solution is too high, too many pores are left after the bone cement is cured, so that the mechanical property is reduced. If the liquid-solid ratio is too low, the solid-liquid phase mixing can not form uniform paste, thereby affecting the bone cement reaction, reducing the injectability and causing the reduction of the mechanical and anti-collapsibility performance of the bone cement. In the embodiment of the invention, the liquid-solid ratio of the curing liquid to the solid-phase powder is optimized, and the mechanical property and the injectability of the bone cement are further improved.
In some embodiments, the curing liquid comprises dipotassium hydrogen phosphate, potassium dihydrogen phosphate, citric acid, and water. Preferably, the solidifying solution further comprises a high molecular compound, and the high molecular compound comprises at least one of sodium alginate or hyaluronic acid. More preferably, the curing liquid comprises 5-20% of dipotassium hydrogen phosphate, 5-20% of monopotassium phosphate, 5-10% of citric acid, 1-5% of high molecular compound and the balance of water by mass percentage. In the embodiment of the invention, the potassium dihydrogen phosphate in the curing liquid can ionize dihydrogen phosphate to promote the reaction of beta-tricalcium phosphate and calcium dihydrogen phosphate monohydrate, the dipotassium hydrogen phosphate and the citric acid can promote the reaction of calcium hydrogen phosphate dihydrate and tetracalcium phosphate, and the dipotassium hydrogen phosphate ionizes hydrogen phosphate ions in the solution, so that the hydroxyapatite can be accelerated to be generated by the calcium hydrogen phosphate dihydrate and the tetracalcium phosphate, meanwhile, the generation of the calcium hydrogen phosphate dihydrate can be inhibited, and the over-short curing time can be avoided. The multiple gradient chemical reaction designed in the embodiment of the invention is a step continuous reaction, and preferably dipotassium hydrogen phosphate, citric acid and potassium dihydrogen phosphate are adopted in the curing liquid to better promote and coordinate the multiple gradient chemical reaction in the embodiment of the invention, so that the curing time of the bone cement is optimized.
The preparation method of the bone cement composite material provided by the embodiment of the invention comprises the following steps: dissolving dipotassium hydrogen phosphate, monopotassium phosphate, citric acid and a high molecular compound in deionized water according to a designed proportion, stirring until the mixture is uniformly mixed to obtain a curing liquid, and mixing the curing liquid with the solid phase powder to obtain the composite material. The preparation method of the composite material provided by the embodiment of the invention is simple and easy to operate, and has a wide application prospect. The present invention is described in detail below with reference to the drawings and examples.
Example 1
1g of beta-tricalcium phosphate, 8g of tetracalcium phosphate and 1g of monocalcium phosphate monohydrate are ground into powder, and the powder is stirred and mixed uniformly to obtain 10g of calcium phosphate powder. And (3) stirring and grinding 5g of the obtained calcium phosphate powder, 3g of bioglass, 1g of calcium sulfate hemihydrate powder and 1g of hydroxyapatite into powder, and uniformly stirring and mixing to obtain solid-phase powder.
Dissolving 1.25g of dipotassium hydrogen phosphate, 1.25g of monopotassium phosphate, 0.75g of citric acid and 0.25g of hyaluronic acid in 5mL of deionized water, uniformly mixing, adding deionized water to dilute the mixed solution, increasing the volume of the obtained mixed solution to 10mL, and uniformly mixing and stirring to obtain a curing solution;
and mixing the curing liquid and the solid-phase powder according to the proportion of 0.7ml/g to form pasty bone cement paste, thereby obtaining the bone cement composite material.
As shown in FIG. 1, this is an XRD pattern of the mixture of the solidified liquid and the solid powder in the present example. After the solidification liquid and the solid-phase powder are mixed for 1min, beta-tricalcium phosphate and calcium dihydrogen phosphate monohydrate which belong to a trigonal system can be found in an XRD (X-ray diffraction) pattern, which indicates that the first step of the multiphase solidification reaction just starts, calcium sulfate hemihydrate can be found in the pattern, and indicates that the calcium sulfate hemihydrate and the liquid phase are not completely reacted; after the curing liquid and the solid-phase powder are mixed for 10min, the XRD (X-ray diffraction) diagram shows that the beta-tricalcium phosphate and the monohydrate monocalcium phosphate are completely consumed, which indicates that the first step of a plurality of curing reactions is completed, and the content of the hydroxyapatite is 10% by full-peak fitting calculation; after the curing liquid and the solid-phase powder are mixed for 1 hour, the content of the hydroxyapatite is 24 percent through full-peak fitting calculation, and the comparison shows that the second step of the multiphase curing reaction is in progress; after the solidification liquid and the solid-phase powder are mixed for 10 hours, a calcium sulfate hemihydrate phase cannot be found in an XRD (X-ray diffraction) diagram, only a calcium sulfate dihydrate phase exists, the calcium sulfate hemihydrate and the liquid phase completely react to generate calcium sulfate dihydrate, and meanwhile, the hydroxyapatite phase is observed to be continuously increased, and the calcium hydrogen phosphate dihydrate phase is continuously reduced. From this, it can be seen that calcium sulfate hemihydrate is already complete and the reaction of tetracalcium phosphate and dicalcium phosphate dihydrate is proceeding in the heterogeneous setting reaction; after the solidification liquid and the solid-phase powder are mixed for 24 hours, the calcium hydrophosphate dihydrate phase disappears, and only a tetracalcium phosphate phase which is not completely consumed and a newly produced hydroxyapatite phase exist, which indicates that a plurality of solidification reactions are basically completed.
The pasty bone cement paste prepared in this example was injected into a syringe and the injectability was tested after 5min to be99％；
The bone cement composite material prepared by the embodiment is placed in a simulated human body environment with 36.5 ℃ and 100% humidity, and the curing time test is carried out, the result is shown in figure 2, and the curing time is 15 min; and after the hydration is continued for 24 hours, taking out the product, placing the product in a universal testing machine, and measuring the compressive strength of the product to be 25MPa, wherein the test result is shown in figure 3.
The bone cement composite material prepared in this example was co-cultured with osteoblasts for 7 days, and the test results are shown in fig. 4, in which the ALP content was 6.72 ± 0.69mg/ml, and the bone cement composite material had good cell activity.
After the bone cement composite material prepared in the present example was soaked with simulated body fluid for 28 days, the measured weight loss was 5.86 ± 0.55%, and the result is shown in fig. 5, which shows good degradability.
Inoculating Staphylococcus aureus in sterilized Nutrient Broth (NB) to an initial colony concentration of 1.85 x 109CFU/ml of golden staphylococcus aureus liquid, then co-culturing the bone cement composite material prepared by the embodiment and the golden staphylococcus liquid for 48 hours, measuring the absorbance (OD) value of 0.21 +/-0.08 at the wavelength of 475nm,the test results are shown in FIG. 6. The OD value of the bone cement composite material prepared by the embodiment is obviously lower than that of a pure CPC group, and the bone cement composite material has good antibacterial property.
Example 2
The solid phase powder was prepared in the same manner as in example 1, except that the solidifying liquid was ionized water.
And mixing the curing liquid and the solid-phase powder according to the proportion of 0.7ml/g to form pasty bone cement paste, thereby obtaining the bone cement composite material.
The bone cement composite material prepared by the embodiment has the injectability of 80 percent, the curing time of 50min and the compressive strength of 20MPa after hydration for 24 h.
Example 3
The solid phase powder was prepared in the same manner as in example 1, except that the amount of Hydroxyapatite (HA) added to the solid phase powder was 0.5g, i.e., the content of hydroxyapatite in the solid phase powder was 5%.
A curing fluid and a bone cement composite were prepared in the same manner as in example 1.
The test was carried out in the same manner as in example 1, the injectability was 99%, the curing time was 20min, and the compressive strength after hydration for 24h was 30 MPa.
Example 4
The solid phase powder was the same as in example 1 except that the amount of bioglass added to the solid phase powder was 1g, i.e., the bioglass content in the solid phase powder was 10%.
A curing fluid and a bone cement composite were prepared in the same manner as in example 1.
The injectability is 99 percent, the curing time is 15min, and the compressive strength is 35MPa after hydration for 24 h.
After the bone cement composite prepared in this example was co-cultured with osteoblasts for 7 days, the ALP activity of the cells was 4.01. + -. 0.46 mg/mL. After being co-cultured with staphylococcus aureus liquid for 48 hours, the OD value at 475nm wavelength is measured to be 0.36 +/-0.04.
Example 5
The solid phase powder was the same as in example 1, except that the amount of calcium sulfate hemihydrate added to the solid phase powder was 2g, i.e., the content of calcium sulfate hemihydrate in the solid phase powder was 20%.
A curing fluid and a bone cement composite were prepared in the same manner as in example 1.
The test was carried out in the same manner as in example 1, and the injectability was 90%, the curing time was 12min, and the compressive strength after hydration for 24h was 18 MPa.
After soaking in simulated body fluid for 28 days, the mass loss was tested to be 8.12 ± 0.65%.
Comparative example 1
The solid phase powder was prepared in the same manner as in example 1, except that the calcium phosphate powder was not supplemented with β -tricalcium phosphate and monocalcium phosphate monohydrate, and calcium hydrogen phosphate dihydrate in a plasma amount was added.
A curing fluid and a bone cement composite were prepared in the same manner as in example 1.
The injectability is 99 percent, the curing time is 13min, and the compressive strength is 20MPa after hydration for 24 h.
ALP of the cells was 6.69. + -. 0.59mg/ml measured 7 days after co-culture with osteoblasts, and OD of the cells was 0.22. + -. 0.06 after co-culture with Staphylococcus aureus solution for 48 hours.
Comparative example 2
8g of tetracalcium phosphate and 2g of calcium hydrogen phosphate dihydrate are stirred and ground into powder, and the powder is uniformly mixed to obtain solid-phase powder.
A curing fluid and a bone cement composite were prepared in the same manner as in example 1.
The calcium phosphate-bioglass cement composite was obtained by performing the test in the same manner as in example 1.
The injectability is 80 percent, the curing time is 30min, and the compressive strength is 22MPa after hydration for 24 h.
After the composite material prepared in comparative example 2 was co-cultured with osteoblasts for 7 days, the ALP activity of the test cells was 3.60. + -. 0.28; after soaking in simulated body fluid for 28 days, the mass loss is tested to be 3.32 +/-0.66%, and the OD value is 0.53 +/-0.10 after the mass loss is co-cultured with staphylococcus aureus liquid for 48 hours.
As can be seen from the above examples and comparative examples, in example 1, the mechanical properties of the bone cement are effectively improved by the multi-phase curing reaction, and compared with the single-phase curing reaction in comparative example 1, the mechanical properties can be improved from 20MPa to 25MPa, and the improvement range is 25%. Compared with the comparative example 2, the injection property is effectively improved, the curing time is shortened, the compressive strength is improved, and the cell activity, the antibacterial property and the degradation property of the preparation are all superior to those of the comparative example 2. Compared with the embodiment 2, the embodiment 1 has the advantages that the phosphate, the citric acid and the hyaluronic acid are added into the curing liquid, so that the curing time is obviously shortened, the mechanical property and the injectability are improved, and therefore, the phosphate, the citric acid and the hyaluronic acid are added into the curing liquid, the cement solidification reaction can be promoted, and the mechanical property and the injectability of the cement are improved. In example 1, compared with example 3, the content of Hydroxyapatite (HA) in the solid phase powder was increased, and the curing time was shortened, but the mechanical properties were decreased. Compared with the embodiment 4, the embodiment 1 has the advantages that the addition amount of the bioglass is increased, the mechanical property is reduced, the ALP activity of cells is effectively increased, the osteogenic property is improved, and the antibacterial property is greatly improved. Compared with the example 5, the dosage of the calcium sulfate hemihydrate is reduced, the degradation speed is reduced, and the injection performance and the mechanical property of the bone cement composite material are improved.
In the present disclosure, the terms "one embodiment," "some embodiments," "an example," "a specific example," or "some examples" and the like mean that a specific feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the present disclosure. In this specification, the schematic representations of the terms used above are not necessarily intended to refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples. Furthermore, various embodiments or examples and features of different embodiments or examples described in this specification can be combined and combined by one skilled in the art without contradiction.
Although embodiments of the present invention have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting the present invention, and that variations, modifications, substitutions and alterations can be made to the above embodiments by those of ordinary skill in the art within the scope of the present invention.

Claims (10)

1. The solid phase powder for the bone cement composite material is characterized by comprising calcium phosphate powder, calcium sulfate hemihydrate powder, bioglass and hydroxyapatite, wherein the calcium phosphate powder comprises the following components in parts by weight: beta-tricalcium phosphate, tetracalcium phosphate and monocalcium phosphate monohydrate.
2. The solid-phase powder for the bone cement composite material according to claim 1, wherein the solid-phase powder comprises 10-80% of calcium phosphate powder, 5-50% of bioglass, 10-25% of calcium sulfate hemihydrate powder and 5-15% of hydroxyapatite by mass percentage.
3. The solid phase powder for a bone cement composite according to claim 1 or 2, wherein the calcium phosphate powder comprises 5-20% of beta-tricalcium phosphate, 60-90% of tetracalcium phosphate and 5-20% of monocalcium phosphate monohydrate by mass percentage.
4. Use of the solid phase powder for a bone cement composite material according to any one of claims 1 to 3 in the preparation of a bone repair material.
5. A bone cement composite material comprising the solid phase powder according to any one of claims 1 to 3 and a solidifying liquid.
6. The bone cement composite material as claimed in claim 5, wherein the liquid-solid ratio of the solidifying liquid to the solid phase powder is 0.5ml/g to 1 ml/g.
7. The bone cement composite according to claim 5 or 6, characterized in that the setting fluid comprises dipotassium hydrogen phosphate, potassium dihydrogen phosphate, citric acid and water.
8. The bone cement composite of claim 7, wherein the setting fluid further comprises a polymeric compound comprising at least one of sodium alginate or hyaluronic acid.
9. The bone cement composite material as claimed in claim 8, wherein the setting fluid comprises 5-20% of dipotassium hydrogen phosphate, 5-20% of monopotassium phosphate, 5-10% of citric acid, 1-5% of high molecular compound, and the balance of water by mass percentage.
10. Use of a bone cement composite according to any one of claims 5-9 for the preparation of a bone repair material.
CN202111439934.1A 2021-11-30 2021-11-30 Solid phase powder for bone cement composite material, bone cement composite material and application Active CN114209878B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111439934.1A CN114209878B (en) 2021-11-30 2021-11-30 Solid phase powder for bone cement composite material, bone cement composite material and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111439934.1A CN114209878B (en) 2021-11-30 2021-11-30 Solid phase powder for bone cement composite material, bone cement composite material and application

Publications (2)

Publication Number Publication Date
CN114209878A true CN114209878A (en) 2022-03-22
CN114209878B CN114209878B (en) 2023-03-14

Family

ID=80698998

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111439934.1A Active CN114209878B (en) 2021-11-30 2021-11-30 Solid phase powder for bone cement composite material, bone cement composite material and application

Country Status (1)

Country Link
CN (1) CN114209878B (en)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980625A (en) * 1997-03-13 1999-11-09 Ngk Spark Plug Co., Ltd. Calcium phosphate composition and a setting solution therefor
CN1559888A (en) * 2004-03-08 2005-01-05 西安交通大学 Preparation process of strontium nano calcium phosphate containing biological active bone cement
CN101816808A (en) * 2010-02-05 2010-09-01 佘振定 Injectable porous high-strength bone repair material
CN101843918A (en) * 2010-05-27 2010-09-29 甘少磊 Composite bone repairing material based on nano-hydroxyapatite and hemihydrate calcium sulfate and preparation method thereof
CN102049062A (en) * 2009-10-30 2011-05-11 华东理工大学 Injectable efficient suspended stable calcium phosphate cement and preparation method and application thereof
US20120031305A1 (en) * 2009-04-17 2012-02-09 Hoya Corporation Calcium phosphate cement composition and its kit for bone prosthesis
CN104056305A (en) * 2014-04-24 2014-09-24 安泰科技股份有限公司 Calcium phosphate-based compound self-setting bone repair material and preparation method thereof
CN108273131A (en) * 2018-03-19 2018-07-13 深圳市中科海世御生物科技有限公司 A kind of composite bone cement, preparation method and applications and a kind of bone renovating material
CN109395160A (en) * 2018-09-21 2019-03-01 广州润虹医药科技股份有限公司 A kind of injectable type bone cement of fast degradation and its application

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980625A (en) * 1997-03-13 1999-11-09 Ngk Spark Plug Co., Ltd. Calcium phosphate composition and a setting solution therefor
CN1559888A (en) * 2004-03-08 2005-01-05 西安交通大学 Preparation process of strontium nano calcium phosphate containing biological active bone cement
US20120031305A1 (en) * 2009-04-17 2012-02-09 Hoya Corporation Calcium phosphate cement composition and its kit for bone prosthesis
CN102049062A (en) * 2009-10-30 2011-05-11 华东理工大学 Injectable efficient suspended stable calcium phosphate cement and preparation method and application thereof
CN101816808A (en) * 2010-02-05 2010-09-01 佘振定 Injectable porous high-strength bone repair material
CN101843918A (en) * 2010-05-27 2010-09-29 甘少磊 Composite bone repairing material based on nano-hydroxyapatite and hemihydrate calcium sulfate and preparation method thereof
CN104056305A (en) * 2014-04-24 2014-09-24 安泰科技股份有限公司 Calcium phosphate-based compound self-setting bone repair material and preparation method thereof
CN108273131A (en) * 2018-03-19 2018-07-13 深圳市中科海世御生物科技有限公司 A kind of composite bone cement, preparation method and applications and a kind of bone renovating material
CN109395160A (en) * 2018-09-21 2019-03-01 广州润虹医药科技股份有限公司 A kind of injectable type bone cement of fast degradation and its application

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
王芳: "硫酸钙和羟基磷灰石对磷酸钙骨水泥的性能影响", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 *

Also Published As

Publication number Publication date
CN114209878B (en) 2023-03-14

Similar Documents

Publication Publication Date Title
US10828396B2 (en) Degradable magnesium-containing calcium phosphate-calcium sulfate porous composite biological scaffold
Dorozhkin Calcium orthophosphate cements and concretes
Dorozhkin Self-setting calcium orthophosphate formulations
US7119038B2 (en) Method for making a porous calcium phosphate article
EP1715829B1 (en) Rapid-hardening calcium phosphate cement compositions
US7417077B2 (en) Composition for an injectable bone mineral substitute material
CN104056305B (en) A kind of calcium orthophosphate base is combined self-curing bone renovating material and preparation method thereof
Cui et al. Evaluation of an injectable bioactive borate glass cement to heal bone defects in a rabbit femoral condyle model
CN102438667A (en) Galliated calcium phosphate biomaterials
CN101816808B (en) Injectable porous high-strength bone repair material
CN105251058B (en) A kind of preparation method for carrying medicine and promoting bone uptake injection-type calcium sulfate bone cement
CN101530630A (en) X-ray developing calcium phosphate cement and preparation method and application thereof
CN114591066B (en) Ceramic calcium phosphate bone cement and preparation method thereof
Cama Calcium phosphate cements for bone regeneration
CN111671969A (en) Injectable vertebral body reinforced magnesium phosphate bone cement and preparation method thereof
CN111773432A (en) Magnesium-based amorphous-calcium phosphate/calcium silicate composite filler and preparation and application thereof
Miao et al. Multi-stage controllable degradation of strontium-doped calcium sulfate hemihydrate-tricalcium phosphate microsphere composite as a substitute for osteoporotic bone defect repairing: degradation behavior and bone response
CN114209878B (en) Solid phase powder for bone cement composite material, bone cement composite material and application
CN109125804A (en) A kind of solidify liquid and the preparation method and application thereof suitable for calcium orthophosphate base bone cement
CN112142439A (en) Stress stimulation type high mineralization activity composite bone cement and preparation method thereof
CN105536059B (en) A kind of selfreparing injecting bone cement and preparation method
CN101816807B (en) Bone repairing material for personalized treatment
CN106620843A (en) Composite bone cement with bioactivity and antibacterial activity as well as preparation method and application
CN112675358B (en) Brushite bone cement and preparation method and application thereof
US20070224286A1 (en) Process for Preparing Calcium Phosphate Self-Setting Bone Cement, the Cement So Prepared and Uses Thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant